Novavax (NVAX) Capital Expenditures (2010 - 2026)
Novavax (NVAX) posted quarterly Capital Expenditures of $1.3 million for Q1 2026, down 20.38% year-over-year from $1.6 million in Q1 2025, and down 76.08% quarter-over-quarter from $5.3 million in Q4 2025.
Novavax (NVAX) Capital Expenditures (2010 - 2026) Analysis & Trends
Novavax's Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Capital Expenditures fell 20.38% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $5.2 million (up 261.03% YoY), while the FY2025 annual figure was $5.6 million, up 423.05% from the prior year.
- Capital Expenditures for Q1 2026 stood at $1.3 million, down from $5.3 million in the prior quarter.
- The five-year high for Capital Expenditures was $66.0 million in Q3 2022, with the low at -$62.1 million in Q4 2022.
- The 5-year median for Capital Expenditures is $985000.0 (2024), against an average of $1.2 million.
- Peak annual rise in Capital Expenditures reached 1076.1% in 2025, while the deepest fall reached 223.55% in 2025.
- Novavax's Capital Expenditures stood at -$62.1 million in 2022, then jumped by 40.37% to -$37.0 million in 2023, then soared by 98.53% to -$544000.0 in 2024, then surged by 1076.1% to $5.3 million in 2025, then plunged by 76.08% to $1.3 million in 2026.
- Business Quant data shows NVAX's Capital Expenditures at $1.3 million in Q1 2026, $5.3 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 588,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 588,000.00 |
| Jun 30, 2026 | 588,000.00 |
| Mar 31, 2026 | 1.27 Mn |
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 5.31 Mn |
| Dec 31, 2025 | 5.31 Mn |
| Sep 30, 2025 | -1.22 Mn |
| Sep 30, 2025 | -1.22 Mn |
| Jun 30, 2025 | -128,000.00 |
| Jun 30, 2025 | -128,000.00 |
| Mar 31, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | -544,000.00 |
| Dec 31, 2024 | -544,000.00 |
| Sep 30, 2024 | 985,000.00 |
| Sep 30, 2024 | 985,000.00 |
| Jun 30, 2024 | -586,000.00 |
| Jun 30, 2024 | -586,000.00 |
| Mar 31, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |